Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912

Date: 03-02-2023

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.
Scrip Code : 524518

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400051.
Scrip Code : KREBSBIO

Dear Sir / Madam,

Sub: Outcome of Board Meeting under Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015:

Further to our letter dated January 23, 2023 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today have approved the following:

1. Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report by the Statutory Auditors thereon - Enclosed.

2. Appointment of Mr. Rohit Taparia as Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the Company Secretary appointed.

3. Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the CFO appointed.

Krebs Biochemicals & Industries Ltd. Hyderabad

4. Resignation of Mr. Ravi Babu as Chief Financial Officer and Key Managerial Personnel of the Company from the closure of business hours on February 3, 2023. Details of the resigned CFO is as below:

1	Name	Mr. Ravi Babu
2	Designation	Chief Financial Officer
3	Reason for change	Resigned from Employment
4	Date of cessation	February 3, 2022
5	Brief Profile	NA
6	Disclosure of Relationship between Directors (in case of appointment of a Director)	NA

5. The Board has decided to maintain the registers, book of accounts and other documents as required to be maintained under the provisions of Companies Act, 2013 at Registered Office of the Company situated at Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 w.e.f 1st April, 2023 from Corporate Office situated at 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034, Andhra Pradesh subject to the approval of shareholders. Postal Ballot Notice shall be shared in due course.

The Meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 03:20 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully

For **Krebs Biochemicals and Industries Limited**

Pabitrakumar Bhattacharyya
Managing Director
Email:com_sec@krebsbiochem.com

Encl: as above

Annexure – I

The continuous disclosure requirement under regulation 30 pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Sl. No	Particulars	Details
1	Reason for change	Appointment of Mr. Rohit Taparia as Company Secretary & Compliance Officer Key Managerial Personnel of the Company in place of resigned Company Secretary and Compliance Officer.
2	Date of appointment & term of appointment	February 3, 2023 and terms as decided by Board of Directors
3	Brief profile (in case of appointment)	Mr. Rohit Taparia (M.No: A35756) is a Company Secretary and LLB (Gen) with overall experience of 8.5 years in the Secretarial and legal compliances. Out of 8.5 years he has served as Company secretary in 2 listed Companies. Also he has worked for private and unlisted public company. Previously, he was associated with IDBI Trusteeship Services Ltd. (subsidiary of IDBI Bank, promoted by IDBI, LIC & GIC).
4	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Rohit Taparia is not related to any Directors of the Company.

Annexure – II

The continuous disclosure requirement under regulation 30 pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Sl. No	Particulars	Details
1	Reason for change	Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company due to resignation of Mr. Ravi Babu, CFO.
2	Date of appointment & term of appointment	February 3, 2023 and terms as decided by Board of Directors
3	Brief profile (in case of appointment)	Mr. Ritesh Jain is a Chartered Accountant with more than 19 years of extensive experience in Accounts Finalization, Direct & Indirect Taxation, Audit – Statutory & internal, management Reporting and Analysis, Project profitability and variance analytics, preparation of budget and variance analysis, Direct Taxation & GST and General Accounting & Reporting. In addition he has proven skills in managing Service Delivery, Client Relationships and Transformation. Before that he was associated with Nahar Builders.
4	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Ritesh Jain is not related to any Directors of the Company.

KREBS BIOCHEMICALS & INDUSTRIES LIMITED
CIN:L24110AP1991PLC103912
Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031
Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022 (Un Audited)	30.09.2022 (Un Audited)	31.12.2021 (Un Audited)	31.12.2022 (Un Audited)	31.12.2021 (Un Audited)	31.03.2022 (Audited)
1	Revenue from Operations	909.07	2,094.25	2,181.00	4,067.39	4054.56	5970.31
2	Other Income	2.29	27.46	20.13	42.69	36.30	115.58
3	**Total Income (1+2)**	**911.36**	**2,121.71**	**2,201.13**	**4,110.08**	**4,090.86**	**6,085.89**
4	**Expenses**						
	a) Cost of Material Consumed	310.97	149.58	1,641.78	1,505.68	3,018.91	4,618.01
	b)Purchase of Stock in Trade	1.58	438.64	-	440.22	-	-
	c) Changes in Inventories of Finished goods, Work-In-Progress	(149.63)	750.27	(86.80)	306.89	(374.38)	(553.79)
	d) Employee Benefits Expenses	391.01	376.32	419.96	1,133.51	1,086.55	1,530.02
	e) Finance Costs	89.82	74.21	182.34	194.47	511.13	539.10
	f) Depreciation and Amortisation Expense	169.28	169.28	141.60	507.84	424.80	629.67
	g) Other Expenses	653.76	569.55	1,196.34	1,796.70	2,745.15	3,775.56
	Total Expenses (4)	**1,466.79**	**2,527.85**	**3,495.22**	**5,885.30**	**7,412.16**	**10,538.57**
5	**Profit / (Loss) before exceptional Items and tax (3-4)**	**(555.43)**	**(406.14)**	**(1,294.09)**	**(1,775.22)**	**(3,321.30)**	**(4,452.68)**
6	**Exceptional Items:**	-	-	-	-	-	-
7	**Profit / (Loss) before Tax (5 ± 6)**	**(555.43)**	**(406.14)**	**(1,294.09)**	**(1,775.22)**	**(3,321.30)**	**(4,452.68)**
8	**Tax Expense**						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	-
9	**Profit / (Loss) for the period (7 ± 8)**	**(555.43)**	**(406.14)**	**(1,294.09)**	**(1,775.22)**	**(3,321.30)**	**(4,452.68)**
10	Other Comprehensive Income (OCI)						
i	Items that will not be reclassified to profit or Loss	-	-	-	-	-	(30.47)
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	-	-		-	(4.17)	(4.17)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-		-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-		-	(4.17)	(34.64)
11	**Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)**	**(555.43)**	**(406.14)**	**(1,294.09)**	**(1,775.22)**	**(3,325.47)**	**(4,487.32)**
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06	2,156.06
13	Other Equity excluding Revaluation Reserve	-	-	-	-	-	(10,770.46)
14	**Earning Per Share (of Rs.10/- each) (not Annualised)**						
	a) Basic	(2.58)	(1.88)	(6.00)	(8.23)	(15.42)	(20.81)
	b) Diluted	(2.58)	(1.88)	(6.00)	(8.23)	(15.42)	(20.81)
15	**Net Worth** (including Retained Earnings)	-	-	-	-	-	(7,509.32)

See accompanying notes to the Financial results

1. The above results have been reviewed by the Audit Committee at its meeting held on 3rd Febuary, 2023 and approved by the Board of Directors of the Company at its meeting held on 3rd February, 2023. The results are subjected to limited review by statutory auditors.
2. The Company is operating in one segment only hence no segment results have been disclosed.
3. The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Krebs Biochemicals & Industries Ltd. Hyderabad

Pabitrakumar Kalipada Bhattacharyya
Managing Director
DIN :07131152

Place: Hyderabad
Date: 03.02.2023

BHAVANI & CO.,
CHARTERED ACCOUNTANTS
Tel : 040-2970 2640

Independent Auditor's Review Report on the Quarterly and year to Date Unaudited standalone Financial Results of the company pursuant to the regulation 33 and 52 of the SEBI(Listing Obligation and Disclosure Requirements)Regulation,2015,as amended

Review Report to
The Board of Directors,
M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED

a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS AND INDUSTRIES LIMITED ("the company") for the quarter** ended **31st December, 2022** and Year to date from April 01,2022 to December 31,2022 (the **"Statement") attached herewith, being submitted by the company pursuant to the requirements** of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended(the **"Listing Regulations")**

b) **The statement, which is the responsibility of the Company's Management and approved by the** Board of Directors ,has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS') specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani & Co
Chartered Accountants
F.R.Number : 012139S

KAVITHA PADMINI SIRIGINA Digitally signed by KAVITHA PADMINI SIRIGINA

Place : Hyderabad
Date : 03-02-2023

(CA S. KAVITHA PADMINI)
Partner
M.No. 229966
UDIN : 23229966BGXVRZ5138

Plot No.48, Flat No.301, Micasa, Phase - I, Kavuri Hills, Hyderabad - 500 033.
E-mail : bhavaniandco@gmail.com